| TIME | TITLE | SPEAKER |
| 8:00–8:30 | Networking, Registration | |
| 8:30–8:35 | Opening Speech | Shidong Jia (Predicine) |
| Session 1 | China for Global: Biomarker & CDx Solutions for Clinical Trials | Chair: Chunxia Su (Shanghai Pulmonary Hospital) |
| 8:35–8:55 | Integrated molecular analysis of NSCLC brain metastasis tissue and multimodal ctDNA reveals distinct signatures of patient outcomes | Darin Dolezel (Yale) |
| 8:55–9:15 | Advancing NMIBC Precision Oncology: Dual Tissue–Urine Assay Strategies to Enhance Clinical Trial Screening & Patient Access | Emily Qing |
| 9:15–9:35 | Advancing Clinical Trial from MRD to Precision Oncology | Eric Matthews (Natera) |
| 9:35–9:55 | Innovative Liquid Biopsy and MRD Solutions for Global Oncology Drug Development | Haoran Tang (Predicine) |
| 9:55–10:20 | Tea Break | |
| Session 2 | MRD: Tumor-informed & Tumor-naive MRD | Chair: Longen Zhou |
| 10:20–10:40 | MRD in Liver Cancer and Beyond: Emerging Clinical Applications | Jie Hu (Zhongshan Hospital) |
| 10:40–11:00 | CSF ctDNA Profiling for Leptomeningeal Metastasis in NSCLC | Haiyang Chen (Henan Cancer Hospital) |
| 11:00–11:20 | Bladder Preservation in MIBC: Clinical Experience from HOPE-03 and Insights from EPIC Biomarker Analysis | Yali Shen (West China Hospital) |
| 11:20–11:40 | What Becomes Possible Combining MRD, Multi-Omics & Real-World Data Insights | David Shames (Natera) |
| 11:40–12:10 |
MRD in Global Clinical Trials: Harmonization, Endpoint Validation & CDx Development Panelists: Morning Session Speakers |
Host: Longen Zhou |
| 12:10–13:30 | Buffet Lunch | |
| Session 3 | Liquid Biopsy in Clinical Practice: Biomarkers, Targets & Indications | Chair: Emily Duan |
| 13:30–13:50 | Use of ctDNA to Inform Radiopharmaceutical Therapy in Advanced Prostate Cancer | Praful Ravi (Harvard) |
| 13:50–14:10 | PD1/CTLA4 Combination Therapy: Biomarker Strategies and Liquid Biopsy Monitoring | Chunxia Su (Shanghai Pulmonary Hospital) |
| 14:10–14:30 | MARIPOSA: Integrated Multi-omic Characterization and Liquid Biopsy-Guided Treatment Decisions in NSCLC with Amivantamab | Xuesong Lyu |
| 14:30–15:00 | Tea Break | |
| 15:00–15:20 | Urine-Based Molecular Profiling of FGFR-Targeted Therapy in Bladder Cancer | Guanglei Zhuang (SJTU) |
| 15:20–15:40 | Urine-Based MRD Detection in Bladder Cancer: A Non-Invasive Approach to Disease Surveillance | Ruiyun Zhang (Renji Hospital) |
| 15:40–16:00 | Early experience with cerebrospinal fluid cell-free DNA molecular profiling in a neuro-oncology practice | Terry Burns (Mayo Clinic) |
| 16:00–16:30 |
Liquid Biopsy in Real-World Practice: Monitoring, Resistance & Mechanism Panelists: Afternoon Session Speakers |
Host: Emily Duan |
| 16:30–16:35 | Closing Remarks | Shidong Jia (Predicine) |